{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:07:38Z","timestamp":1791799658638,"version":"4.3.4"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejmech.2021.114046","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T18:37:29Z","timestamp":1639247849000},"page":"114046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Design, synthesis and in\u00a0vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4815-1732","authenticated-orcid":false,"given":"Julia K.","family":"Stille","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jevgenijs","family":"Tjutrins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6792-3091","authenticated-orcid":false,"given":"Guanyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Venegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8879-1481","authenticated-orcid":false,"given":"Christopher","family":"Hennecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s M.","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Blaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin E.","family":"Miron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-3098","authenticated-orcid":false,"given":"Sharon","family":"Pinus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-3928","authenticated-orcid":false,"given":"Anne","family":"Labarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8032-2047","authenticated-orcid":false,"given":"Jessica","family":"Plescia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9289-7887","authenticated-orcid":false,"given":"Mihai","family":"Burai Patrascu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Wahba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6118-9300","authenticated-orcid":false,"given":"Danielle","family":"Vlaho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell J.","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-0436","authenticated-orcid":false,"given":"T. Martin","family":"Schmeing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K.","family":"Mittermaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6933-2079","authenticated-orcid":false,"given":"Nicolas","family":"Moitessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.114046_bib3","doi-asserted-by":"crossref","first-page":"E218","DOI":"10.1016\/S2666-5247(20)30089-6","article-title":"SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study","volume":"1","author":"Schlottau","year":"2020","journal-title":"Lancet Micr"},{"key":"10.1016\/j.ejmech.2021.114046_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virusres.2007.03.012","article-title":"A\u00a0review of studies on animal reservoirs of the SARS coronavirus","volume":"133","author":"Shi","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.ejmech.2021.114046_bib5","doi-asserted-by":"crossref","first-page":"E666","DOI":"10.1503\/cmaj.200711","article-title":"Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States","volume":"192","author":"Abdollahi","year":"2020","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.ejmech.2021.114046_bib7","series-title":"WHO Coronavirus Disease","author":"Organization","year":"2020"},{"key":"10.1016\/j.ejmech.2021.114046_bib8","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1038\/s41467-021-22944-0","article-title":"Estimating COVID-19 mortality in Italy early in the COVID-19 pandemic","volume":"12","author":"Modi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.114046_bib9","series-title":"Pfizer's CEO Says Covid Vaccine Effectiveness Drops to 84% after Six Months","author":"Stankiewicz","year":"2021"},{"key":"10.1016\/j.ejmech.2021.114046_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/d41586-021-01505-x","article-title":"Six months of COVID vaccines: what 1.7 billion doses have taught scientists","volume":"594","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.114046_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2021.114046_bib12","article-title":"The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data","author":"Chodick","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.114046_bib13","series-title":"An Oral COVID-19 Antiviral Medicine","author":"Merck","year":"2021"},{"key":"10.1016\/j.ejmech.2021.114046_bib14","article-title":"Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities","author":"Cannalire","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A\u00a0pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.114046_bib16","series-title":"Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China","author":"Wu","year":"2020"},{"key":"10.1016\/j.ejmech.2021.114046_bib17","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c01252","article-title":"Structure-guided optimization of dipeptidyl inhibitors of norovirus 3CL protease","author":"Rathnayake","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib18","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1016\/j.bmc.2008.06.015","article-title":"Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents","volume":"16","author":"Kuo","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib19","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1021\/jm9805384","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human Rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as l-glutamine replacements","volume":"42","author":"Dragovich","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.114046_bib21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41401-020-0483-6","article-title":"Anti-SARS-CoV-2 activities in\u00a0vitro of Shuanghuanglian preparations and bioactive ingredients","volume":"41","author":"Su","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2021.114046_bib22","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.str.2020.10.007","article-title":"Malleability of the SARS-CoV-2 3CL Mpro active-site cavity facilitates binding of clinical antivirals","volume":"28","author":"Kneller","year":"2020","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2021.114046_bib23","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1038\/s41467-020-16954-7","article-title":"Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography","volume":"11","author":"Kneller","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.114046_bib24","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome\u2013coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.114046_bib26","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1038\/s41467-020-18096-2","article-title":"Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.114046_bib28","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.114046_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2021.114046_bib30","series-title":"Rational Design of a New Class of Protease Inhibitors for the Potential Treatment of Coronavirus Diseases","author":"Westberg","year":"2020"},{"key":"10.1016\/j.ejmech.2021.114046_bib31","article-title":"Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Iketani","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.114046_bib32","series-title":"Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19","author":"Boras","year":"2021"},{"key":"10.1016\/j.ejmech.2021.114046_bib33","article-title":"The discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","author":"Hoffman","year":"2020","journal-title":"ChemRxiv"},{"key":"10.1016\/j.ejmech.2021.114046_bib34","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib35","series-title":"Study of PF-07321332 in Healthy Participants - NCT04756531","year":"2021"},{"key":"10.1016\/j.ejmech.2021.114046_bib36","unstructured":"D.R. Owen, C.M.N. Allerton, A.S. Anderson, L. Aschenbrenner, M. Avery, S. Berritt, B. Boras, R.D. Cardin, A. Carlo, K.J. Coffman, A. Dantonio, L. Di, H. Eng, R. Ferre, K.S. Gajiwala, S.A. Gibson, S.E. Greasley, B.L. Hurst, E.P. Kadar, A.S. Kalgutkar, J.C. Lee, J. Lee, W. Liu, S.W. Mason, S. Noell, J.J. Novak, R.S. Obach, K. Ogilvie, N.C. Patel, M. Pettersson, D.K. Rai, M.R. Reese, M.F. Sammons, J.G. Sathish, R.S.P. Singh, C.M. Steppan, A.E. Stewart, J.B. Tuttle, L. Updyke, P.R. Verhoest, L. Wei, Q. Yang, Y. Zhu, An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19, Science, 0 eabl4784."},{"key":"10.1016\/j.ejmech.2021.114046_bib37","series-title":"Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization O Death by 89% in Iterim Analysis of Phase 2\/3 EPIC-HR Study","year":"2021"},{"key":"10.1016\/j.ejmech.2021.114046_bib38","article-title":"Peptidomimetic \u03b1-acyloxymethylketone warheads with six-membered lactam P1 glutamine mimic: SARS-CoV-2 3CL protease inhibition, coronavirus antiviral activity, and in\u00a0vitro biological stability","author":"Bai","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib39","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1039\/D1MD00247C","article-title":"Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Bai","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib40","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib41","article-title":"Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor","volume":"12","author":"Kim","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2021.114046_bib42","doi-asserted-by":"crossref","first-page":"113584","DOI":"10.1016\/j.ejmech.2021.113584","article-title":"Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: structural enhancements, increased solubility, and micellar studies","volume":"222","author":"Vuong","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib43","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1016\/j.bmcl.2005.04.027","article-title":"Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors","volume":"15","author":"Chen","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114046_bib44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bioorg.2008.01.001","article-title":"Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase","volume":"36","author":"Zhang","year":"2008","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib45","doi-asserted-by":"crossref","DOI":"10.1021\/acscentsci.1c00039","article-title":"Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug Perampanel guided by free energy perturbation calculations","author":"Zhang","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2021.114046_bib46","series-title":"Drug Repurposing Screen Identifies Masitinib as a 3CLpro Inhibitor that Blocks Replication of SARS-CoV-2 in\u00a0Vitro","author":"Drayman","year":"2020"},{"key":"10.1016\/j.ejmech.2021.114046_bib47","doi-asserted-by":"crossref","DOI":"10.1021\/acsptsci.0c00108","article-title":"Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening","author":"Zhu","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2021.114046_bib48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2017.06.019","article-title":"Covalent inhibitors design and discovery","volume":"138","author":"De Cesco","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib49","series-title":"Drug Bioactivation, Covalent Binding to Target Proteins and Toxicity Relevance","first-page":"41","author":"Zhou","year":"2005"},{"key":"10.1016\/j.ejmech.2021.114046_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1021\/cen-v089n036.p019","article-title":"Covalent drugs form long-lived ties","volume":"89","author":"Guterman","year":"2011","journal-title":"C&EN"},{"key":"10.1016\/j.ejmech.2021.114046_bib51","series-title":"AI-aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2","author":"Tang","year":"2020"},{"key":"10.1016\/j.ejmech.2021.114046_bib52","series-title":"Potentially Highly Potent Drugs for 2019-nCoV","author":"Nguyen","year":"2020"},{"key":"10.1016\/j.ejmech.2021.114046_bib53","series-title":"Finding Potent Inhibitors against SARS-CoV-2 Main Protease through Virtual Screening, ADMET, and Molecular Dynamic Simulation Studies","author":"Roy","year":"2020"},{"key":"10.1016\/j.ejmech.2021.114046_bib54","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1021\/acs.jmedchem.5b01296","article-title":"3-Oxo-hexahydro-1H-isoindole-4-carboxylic acid as a drug chiral bicyclic scaffold: structure-based design and preparation of conformationally constrained covalent and noncovalent prolyl oligopeptidase inhibitors","volume":"59","author":"Mariaule","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib55","doi-asserted-by":"crossref","first-page":"111783","DOI":"10.1016\/j.ejmech.2019.111783","article-title":"Discovery of covalent prolyl oligopeptidase boronic ester inhibitors","volume":"185","author":"Plescia","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib56","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm301580n","volume":"56","author":"Jacobs","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib57","series-title":"An Automatic Pipeline for the Design of Irreversible Derivatives Identifies a Potent SARS-CoV-2 Mpro Inhibitor","author":"Zaidman","year":"2020"},{"key":"10.1016\/j.ejmech.2021.114046_bib58","series-title":"Structure of COVID-19 Main Protease Bound to Potent Broad-Spectrum Non-covalent Inhibitor X77","author":"Mesecar","year":"2020"},{"key":"10.1016\/j.ejmech.2021.114046_bib59","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/acs.accounts.6b00185","article-title":"Medicinal chemistry projects requiring imaginative structure-based drug design methods","volume":"49","author":"Moitessier","year":"2016","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2021.114046_bib60","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1055\/s-2004-817764","article-title":"Substituted 2-(Cyanomethyl-amino)-acetamides by a novel three-component reaction","author":"Behnke","year":"2004","journal-title":"Synlett"},{"key":"10.1016\/j.ejmech.2021.114046_bib61","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1021\/ol025986r","article-title":"Liquid-phase combinatorial synthesis of alicyclic \u03b2-lactams via Ugi four-component reaction","volume":"4","author":"Gedey","year":"2002","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2021.114046_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/17518253.2010.524168","article-title":"An efficient, catalyst- and solvent-freeN-formylation of aromatic and aliphatic amines","volume":"4","author":"Dhake","year":"2011","journal-title":"Green Chem. Lett. Rev."},{"key":"10.1016\/j.ejmech.2021.114046_bib63","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1039\/D0GC02722G","article-title":"Isocyanide 2.0","volume":"22","author":"Patil","year":"2020","journal-title":"Green Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib64","series-title":"Broad Spectrum Non-covalent Coronavirus Protease Inhibitors","author":"St John","year":"2018"},{"key":"10.1016\/j.ejmech.2021.114046_bib65","doi-asserted-by":"crossref","first-page":"112836","DOI":"10.1016\/j.ejmech.2020.112836","article-title":"An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases","volume":"207","author":"Petri","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib66","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1016\/j.bmcl.2013.08.112","article-title":"Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding","volume":"23","author":"Turlington","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114046_bib67","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/s41467-018-03263-3","article-title":"Rapid measurement of inhibitor binding kinetics by isothermal titration calorimetry","volume":"9","author":"Di Trani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.114046_bib68","series-title":"Data Reduction and ErrorAnalysis for the Physical Sciences","author":"Bevington","year":"1992"},{"key":"10.1016\/j.ejmech.2021.114046_bib69","article-title":"Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors","author":"Kitamura","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114046_bib70","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.0c00815","article-title":"Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19","author":"Steuten","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.114046_bib71","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-021-00558-8","article-title":"Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejmech.2021.114046_bib72","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1038\/nprot.2006.463","article-title":"Thermal and high pressure intramolecular Diels\u2013Alder reaction of vinylsulfonamides","volume":"1","author":"Rogachev","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2021.114046_bib73","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jmb.2006.11.073","article-title":"Production of authentic SARS-CoV Mpro with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction","volume":"366","author":"Xue","year":"2007","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.114046_bib74","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0022-2836(83)80284-8","article-title":"Studies on transformation of Escherichia coli with plasmids","volume":"166","author":"Hanahan","year":"1983","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.114046_bib75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1745-7254.2005.00010.x","article-title":"Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique","volume":"26","author":"Chen","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2021.114046_bib76","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J.\u00a0Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2021.114046_bib77","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1107\/S2059798317000079","article-title":"Validation and extraction of molecular-geometry information from small-molecule databases","volume":"73","author":"Long","year":"2017","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.ejmech.2021.114046_bib78","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1107\/S2059798317016035","article-title":"CCP4i2: the new graphical user interface to the CCP4 program suite","volume":"74","author":"Potterton","year":"2018","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.ejmech.2021.114046_bib79","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1107\/S0907444904019079","article-title":"Direct incorporation of experimental phase information in model refinement","volume":"60","author":"Skub\u00e1k","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2021.114046_bib80","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:38:28Z","timestamp":1759329508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421008953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":76,"alternative-id":["S0223523421008953"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114046","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2021-5twk7-v3","asserted-by":"object"}]},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and in\u00a0vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114046"}}